Skip to main content

Table 3 Summary of irAEs

From: Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort

irAE

Patients, n (%)

Any grade

Grade 3/4

Total

286 (33)

55 (6)

Pruritus

58 (7)

1 (<1)

Rash

64 (8)

4 (<1)

Diarrhoea

60 (7)

19 (2)

Nausea

47 (6)

2 (<1)

Vomiting

15 (2)

2 (<1)

Constipation

7 (1)

1 (<1)

Abdominal pain

11 (1)

0

Endocrine

7 (1)

1 (<1)

Liver toxicity

19 (2)

15 (2)

Fatigue/asthenia

70 (8)

10 (1)

  1. irAEs: immune-related adverse events.